Cancer research at BESSY II: Binding Mechanisms of Therapeutic Substances Deciphered
The study is displayed on the cover of the journal Chemmedchem. © Chemmedchem/VCH Wiley
In tumor cells, the DNA is altered in comparison to normal body cells. How such changes can be prevented or inhibited is an exciting field of research with great relevance for the development of cancer treatments. An interdisciplinary team has now analysed the possible binding mechanisms in certain therapeutic substances from the tetrazole hydrazide group using protein crystallography at BESSY II.
Certain proteins such as human histone demethylases, including the KDM4 protein, play a role in the development of tumour cells. They bind to the DNA and modify it so that the cell can become cancerous. Therapeutic substances that are able to inhibit or even reverse such changes are of particular interest.
Biochemist Prof. Dr. Udo Heinemann from the Max Delbrück Centre in Berlin-Buch is investigating such processes. In cooperation with chemists led by Prof. Dr. Andreas Link from the University of Greifswald and the team led by Dr. Manfred Weiss at the HZB, he has now investigated how and where certain therapeutic substances from the tetrazole hydrazide group dock to these protein molecules and thus inhibit their harmful effect.
KDM4 protein crystals analysed
Link initially produced variations of tetrazole hydrazide substances. For structural analysis, crystals had to be grown from KDM4 proteins - a difficult task that Dr. Piotr Malecki and Manfred Weiss had taken on at the HZB. The KDM4 protein crystals were then soaked in a specific substance before being analyzed with strong X-rays on the MX beamlines of BESSY II. A refined analysis showed not only the three-dimensional architecture of the KDM4 protein, but also exactly where the active substances had docked to the KDM4 molecule.
"This class of substances has not yet been structurally investigated," explains Manfred Weiss. And Udo Heinemann from the MDC explains: "We will now evaluate where there are opportunities to dock even stronger within the 3D structure of the KDM4. Then we might also be able to develop drugs that inhibit the KDM4 even more and thus have the potential to become a therapeutic."
- 10 million euros in funding for UNITE – Startup Factory Berlin-BrandenburgUNITE – Startup Factory Berlin-Brandenburg has been recognised by the Federal Ministry for Economic Affairs and Energy as one of ten nationwide flagship projects for science-based start-ups. UNITE is to be established as a central transfer platform for technology-driven spin-offs from science and industry in the capital region. The Helmholtz Centre Berlin will also benefit from this.
- Helmholtz Doctoral Award for Hanna TrzesniowskiDuring her doctoral studies at the Helmholtz Centre Berlin, Hanna Trzesniowski conducted research on nickel-based electrocatalysts for water splitting. Her work contributes to a deeper understanding of alkaline water electrolysis and paves the way for the development of more efficient and stable catalysts. On 8 July 2025, she received the Helmholtz Doctoral Prize, which honours the best and most original doctoral theses in the Helmholtz Association.
- New department at HZB: ‘AI and Biomolecular Structures’Since 1 July 2025, Dr. Andrea Thorn has been setting up the new AI and Biomolecular Structures department at HZB. A biophysicist with many years of experience in AI-based tools for structural biology, she is looking forward to collaborating closely with the macromolecular crystallography team at the MX beamlines of BESSY II.